KNSA on Nasdaq
Kiniksa Pharmaceuticals International, plc
Pharmaceutical preparations company, listed on Nasdaq (KNSA).
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Ultragenyx Pharmaceutical Inc., SUPERNUS PHARMACEUTICALS, INC. or Axsome Therapeutics, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
11.4%Operating margin2
8.7%Net margin2
60.1%Revenue growth, 20252
10.4%Return on equity2
$136.4MFree cash flow2
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue11¢$77.7M
- Research and development14¢$96.9M
- Selling, general and admin29¢$196.3M
- Other costs32¢$217.9M
- Income tax4¢$29.9M
- Profit9¢$59.0M
Out of $677.6M in revenue.2
Where each dollar of operating cash went, fiscal 2025
- Capital spending1¢$1.6M
- Kept or used elsewhere99¢$136.4M
Out of $138.0M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M |
| Cost of goods sold | $77.7M | $60.9M | $33.4M |
| Collaboration expenses | $229.5M | $128.3M | $56.5M |
| Research and development | $96.9M | $111.6M | $76.1M |
| Selling, general and administrative | $196.3M | $168.0M | $129.4M |
| Total operating expenses | $600.3M | $468.9M | $295.5M |
| Income (loss) from operations | $77.2M | -$45.6M | -$25.2M |
| Other income, net | $11.6M | $9.5M | $8.5M |
| Income (loss) before income taxes | $88.9M | -$36.2M | -$16.7M |
| Benefit (provision) for income taxes | -$29.9M | -$7.0M | $30.7M |
| Net income (loss) | $59.0M | -$43.2M | $14.1M |
| Net income (loss) per share attributable to ordinary shareholders, basic | $0.80 | -$0.60 | $0.20 |
| Net income (loss) per share attributable to ordinary shareholders, diluted | $0.75 | -$0.60 | $0.20 |
| Weighted average ordinary shares outstanding, basic | 74.2M shares | 71.4M shares | 70.1M shares |
| Weighted average ordinary shares outstanding, diluted | 79.0M shares | 71.4M shares | 71.9M shares |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | $138.0K | -$169.0K | -$38.0K |
| Total other comprehensive income (loss) | $138.0K | -$169.0K | -$38.0K |
| Total comprehensive income (loss) | $59.1M | -$43.4M | $14.0M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $165.6M | $183.6M | |||
| Short-term investments | $248.5M | $60.0M | |||
| Accounts receivable, net | $15.6M | $41.7M | |||
| Inventory | $54.9M | $26.4M | |||
| Prepaid expenses and other current assets | $42.6M | $20.1M | |||
| Total current assets | $527.2M | $331.8M | |||
| Property and equipment, net | $1.9M | $662.0K | |||
| Operating lease right-of-use assets | $9.8M | $10.4M | |||
| Other long-term assets | $11.3M | $10.3M | |||
| Intangible asset, net | $15.2M | $16.2M | $20.0M | ||
| Deferred tax assets | $198.1M | $211.2M | |||
| Total assets | $763.6M | $580.6M | |||
| Accounts payable | $2.0M | $2.0M | |||
| Accrued collaboration expenses | $70.0M | $48.2M | |||
| Accrued expenses | $42.0M | $32.4M | |||
| Operating lease liabilities | $3.0M | $2.0M | |||
| Other current liabilities | $22.1M | $16.1M | |||
| Total current liabilities | $139.2M | $100.6M | |||
| Non-current deferred revenue | $31.8M | $31.8M | |||
| Non-current operating lease liabilities | $6.5M | $7.9M | |||
| Other long-term liabilities | $18.5M | $1.8M | |||
| Total liabilities | $196.0M | $142.1M | |||
| Additional paid-in capital | $1.0B | $959.7M | |||
| Accumulated other comprehensive loss | -$25.0K | -$163.0K | |||
| Accumulated deficit | -$462.1M | -$521.1M | |||
| Total shareholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | |
| Total liabilities and shareholders' equity | $763.6M | $580.6M | |||
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $165.6M | $183.6M | |||
| Short-term investments | $248.5M | $60.0M | |||
| Accounts receivable, net | $15.6M | $41.7M | |||
| Inventory | $54.9M | $26.4M | |||
| Prepaid expenses and other current assets | $42.6M | $20.1M | |||
| Total current assets | $527.2M | $331.8M | |||
| Property and equipment, net | $1.9M | $662.0K | |||
| Operating lease right-of-use assets | $9.8M | $10.4M | |||
| Other long-term assets | $11.3M | $10.3M | |||
| Intangible asset, net | $15.2M | $16.2M | $20.0M | ||
| Deferred tax assets | $198.1M | $211.2M | |||
| Total assets | $763.6M | $580.6M | |||
| Accounts payable | $2.0M | $2.0M | |||
| Accrued collaboration expenses | $70.0M | $48.2M | |||
| Accrued expenses | $42.0M | $32.4M | |||
| Operating lease liabilities | $3.0M | $2.0M | |||
| Other current liabilities | $22.1M | $16.1M | |||
| Total current liabilities | $139.2M | $100.6M | |||
| Non-current deferred revenue | $31.8M | $31.8M | |||
| Non-current operating lease liabilities | $6.5M | $7.9M | |||
| Other long-term liabilities | $18.5M | $1.8M | |||
| Total liabilities | $196.0M | $142.1M | |||
| Additional paid-in capital | $1.0B | $959.7M | |||
| Accumulated other comprehensive loss | -$25.0K | -$163.0K | |||
| Accumulated deficit | -$462.1M | -$521.1M | |||
| Total shareholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | |
| Total liabilities and shareholders' equity | $763.6M | $580.6M | |||
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 |
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $59.0M | -$43.2M | $14.1M |
| Depreciation and amortization expense | $1.6M | $1.7M | $2.3M |
| Share-based compensation expense | $37.0M | $30.7M | $27.1M |
| Non-cash lease expense | $3.7M | $3.1M | $3.1M |
| Net amortization (accretion) of discounts on short-term investments | -$916.0K | $441.0K | -$1.1M |
| Net (gain) loss on disposal of property and equipment | -$120.0K | -$24.0K | $179.0K |
| Deferred income taxes | $13.0M | $8.1M | -$33.8M |
| Prepaid expenses and other current assets | -$22.5M | -$2.7M | -$7.1M |
| Accounts receivable, net | $26.1M | -$20.5M | -$8.6M |
| Inventory | -$28.5M | $4.8M | -$9.5M |
| Contract asset | $7.7M | ||
| Other long-term assets | -$1.2M | -$9.7M | $4.6M |
| Accounts payable | $142.0K | -$6.3M | $347.0K |
| Accrued expenses, accrued collaboration expenses and other current liabilities | $37.5M | $43.7M | $16.9M |
| Operating lease liabilities | -$3.5M | -$4.0M | -$3.3M |
| Deferred revenue | $19.6M | $261.0K | |
| Other long-term liabilities | $16.7M | -$35.0K | $19.0K |
| Net cash provided by operating activities | $138.0M | $25.7M | $13.3M |
| Proceeds from sale of property and equipment | $25.0K | ||
| Purchases of property and equipment | -$1.6M | -$277.0K | -$130.0K |
| Purchases of short-term investments | -$386.9M | -$202.0M | -$204.9M |
| Proceeds from the maturities of short-term investments | $199.5M | $239.9M | $175.5M |
| Net cash provided by (used in) investing activities | -$189.0M | $37.7M | -$29.6M |
| Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan | $40.8M | $17.2M | $3.7M |
| Payments in connection with ordinary stock tendered for employee tax obligations | -$7.7M | -$5.0M | -$2.2M |
| Net cash provided by financing activities | $33.0M | $12.3M | $1.5M |
| Net increase (decrease) in cash and cash equivalents | -$18.0M | $75.6M | -$14.8M |
| Cash paid for income taxes, net | $3.0M | $2.0M | $5.6M |
| Change in right-of-use asset as a result of new, modified, and terminated leases | $3.1M | $1.6M | $9.6M |
| Additions to property and equipment included in accrued expenses and other liabilities | $83.0K | $153.0K | $54.0K |
No quarter-by-quarter statement was filed.
Compare Kiniksa Pharmaceuticals International, plc with another company
Leadership
Who has led Kiniksa Pharmaceuticals International, plc, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
20202025
- Chief executive officerSanj K. Patel May 23, 2018 to now15
- ChairSanj K. Patel May 23, 2018 to now15
- PresidentStephen F. Mahoney May 23, 2018 to Sep 19, 201916
- Chief financial officerMark Ragosa Dec 23, 2020 to now17
- Chief financial officerChris Heberlig May 23, 2018 to Sep 19, 201918
- Chief operating officerRoss Moat Apr 3, 2026 to now19
- Chief operating officerEben Tessari Mar 18, 2022 to Apr 3, 202620
- Chief operating officerStephen F. Mahoney May 23, 2018 to Sep 19, 201916
Board members and other officers (19)
- CHIEF STRATEGY OFFICERDhiraj H. Malkani Jul 6, 2026 to now21
- Group VP & Rilonacept GMRoss Moat Apr 15, 2021 to now22
- Chief Clinical Dev. OfficerArian Pano Jun 21, 2021 to Sep 7, 202123
- Chief Business OfficerEben Tessari Jun 21, 2021 to now24
- Chief Accounting OfficerMichael R. Megna Feb 13, 2020 to now25
- Chief Commercial OfficerQasim Rizvi Nov 25, 2019 to Jan 5, 202126
- Chief Medical OfficerJohn Paolini May 23, 2018 to now27
- Board memberMeta Cantey Boyd Oct 8, 2024 to Oct 8, 202428
- Board memberG. Bradley Cole Jul 29, 2020 to now29
- Board memberBarry D. Quart May 23, 2018 to now30
- Board memberBihua Chen May 23, 2018 to May 31, 201831
- Board memberFelix Baker May 23, 2018 to now32
- Board memberJulian Baker May 23, 2018 to now32
- Board memberKimberly J. Popovits May 23, 2018 to now33
- Board memberL.p. 667 May 23, 2018 to now32
- Board memberStephen R. Biggar May 23, 2018 to May 23, 201834
- Board memberThomas Malley May 23, 2018 to now35
- Board memberTracey L. McCain May 23, 2018 to now36
- General counselThomas W. Beetham May 23, 2018 to Mar 23, 202137
Former names
- Kiniksa Pharmaceuticals, Ltd.Feb 27, 2018 to Jun 28, 20243
Timeline
- May 23, 2018New chief executive Sanj K. Patel becomes CEO15
Filings
507 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 262 insider forms, 38 large holders, 143 other. The latest 20:
- Sep 3, 2026144 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 21, 20264 EDGAR
- Aug 4, 20264 EDGAR
- Jul 31, 20264 EDGAR
- Jul 29, 2026SCHEDULE 13G EDGAR
- Jul 29, 2026144 EDGAR
- Jul 29, 2026144 EDGAR
- Jul 28, 20268-K EDGAR
- Jul 28, 202610-Q EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20263 EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
The 507 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 38 such filings since October 2021, the latest 10:
- Jul 29, 2026SCHEDULE 13G
- May 26, 2026SCHEDULE 13D/A
- May 6, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Mar 6, 2026SCHEDULE 13G
- Feb 13, 2026SCHEDULE 13G/A
- Oct 31, 2025SCHEDULE 13G/A
- Jul 9, 2025SCHEDULE 13G/A
- May 14, 2025SCHEDULE 13G/A
- Apr 4, 2025SCHEDULE 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARStephen F. Mahoney, President
- 17SEC EDGARMark Ragosa, Chief financial officer
- 18
- 19SEC EDGARRoss Moat, Chief operating officer
- 20
- 21
- 22SEC EDGARRoss Moat, Group VP & Rilonacept GM
- 23
- 24SEC EDGAREben Tessari, Chief Business Officer
- 25
- 26
- 27SEC EDGARJohn Paolini, Chief Medical Officer
- 28SEC EDGARMeta Cantey Boyd, Board member
- 29SEC EDGARG. Bradley Cole, Board member
- 30SEC EDGARBarry D. Quart, Board member
- 31SEC EDGARBihua Chen, Board member
- 32SEC EDGARFelix Baker, Board member
- 33SEC EDGARKimberly J. Popovits, Board member
- 34SEC EDGARStephen R. Biggar, Board member
- 35SEC EDGARThomas Malley, Board member
- 36SEC EDGARTracey L. McCain, Board member
- 37SEC EDGARThomas W. Beetham, General counsel